ENDO - Sorrento Receives FDA Approval For ZTlido Which Had A Long Road To Approval
Recently, Sorrento Therapeutics (SRNE) announced that it had received FDA Approval for its pain patch ZTlido. This patch was approved by the FDA for the relief of pain associated with post-herpetic neuralgia (PHN). Another way to think of this is as post-shingles pain. The stock has traded lower since then, but I believe it offers a great buying opportunity. The reason being is because this pain patch is expected to generate peak sales of over $1 billion. Therefore, there is plenty of room for share price appreciation. Especially, since its market cap